Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2000-11-09
2003-06-03
Priebe, Scott D. (Department: 1635)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S243000, C435S320100, C435S325000, C435S348000, C435S349000, C435S352000, C435S410000, C435S455000, C435S468000, C435S471000, C536S023500, C536S023400
Reexamination Certificate
active
06573069
ABSTRACT:
BACKGROUND OF THE INVENTION
The Ras family of proteins is comprised of small GTPases that are subdivided into several sub-families known to be involved in diverse cellular actions, such as cell proliferation, differentiation and apoptosis. Moreover, Ras is a known oncogene, and the Ras protein is implicated in oncogenic cell transformation through complex signaling pathways that employ an increasing number of downstream effectors. Some of these effectors are included in Ras sub-families, such as, for example, the Rho subfamily of small GTPases.
The Rho family proteins are implicated in regulating diverse cellular processes as well. One prominent Rho activity comprises effecting actin cytoskeletal organization. Such activities include regulating cell shape, cell attachment and adhesion, cell motility and invasion, cell-cell interactions, cell proliferation, differentiation and apoptosis. For example, Rac1; RhoA and Cdc42 are all implicated in promoting cell motility and invasion. As such, these proteins may be involved in promoting motility, invasiveness and metastasis of tumor cells. In addition, disassembly of actin stress fibers is associated with malignant transformation. Moreover, another prominent and distinct Rho activity includes activation of signaling cascades that enhance gene expression through the induction of various transcription factors, resulting in cell proliferation, cell cycle progression, differentiation and apoptosis. For Example, the Rho proteins Rac1 and Cdc42 activate Jun NH
2
-terminal kinases (JNKs), which in turn activate Jun, ATF-2 and Elk-1 nuclear transcription factors. Rho family proteins can also activate NF&kgr;B and SRF transcription factors. Virally transduced and mutated versions of cellular Fos, Jun, and NF&kgr;B were originally identified as potent retroviral oncogenes implicated in various tumors and cancerous states (Bishop, J. M.,
Cell
64:235-238, 1991). Thus, Rho family mediated changes in gene expression likely contribute to their proliferative actions, and play a role in cell transformation and cancer. Moreover, several Rho family proteins have been shown to be important for Ras transforming activity. For reference, see Zohn, I. M. et al.,
Oncogene
17:1415-1438, 1998; Maruta, H. et al.,
Microsc. Res. Tech
. 47:61-66, 1999; Aspenstrom, P.
Exper. Cell. Res
. 246:20-25, 1999; Banyard, J. and Zetter, B. R., Cancer and
Metast. Rev
. 17:449-458, 1999; and, Michiels, F. and Collard, J. G.,
Biochem Soc. Symp
. 65:125-146, 1999.
In addition, several effector proteins are known to bind Rho family members, such as Cdc42 and Rac. The effectors that bind Cdc42/Rac have a consensus binding motif designated the Cdc42/Rac Interactive Binding (CRIB) motif (Burbelo, P. D. et al.,
J. Biol. Chem
. 270:29071-29074, 1995). These effectors show GTP-dependent interaction with Cdc42 and/or Rac1, and may or may not show kinase activity. For Example, the Cdc42 effector, MSE55 is a non-kinase effector that specifically binds Cdc42 in a GTP-dependent manner, is localized to membrane ruffles, and induces long actin-based protrusions or cellular extensions in fibroblast cells (Burbelo, P. D. et al.,
Proc. Natl. Acad. Sci. USA
96:9083-9088, 1999). For other references on Cdc2/Rac and their effects on membrane ruffling, actin stress fibers, lamellipodia and the like, see, for example, Ridley, A. J. et al.,
Cell
70:401-410, 1992; and Nobes, C. D., and Hall, A.
Cell
81:53-62, 1995. Other CRIB proteins are implicated in human disease, such as the Wiskott-Aldrich Syndrome, which is an X-linked recessive disorder characterized by thrombocytopenia, recurrent infections due to defective T- and B-cell function, and eczema. The CRIB protein Wiskott-Aldrich Syndrome Protein (WASP) is mutated in this disease, and it is also a Cdc42 effector (Symons, M. et al.,
Cell
84:723-734, 1996). Because these CRIB proteins influence members of the Rho family of proteins, these effectors may also play a role in cell proliferation, transformation, motility and metastasis. For reference, see Zohn, I. M. et al., supra.
Considering the importance of this family of proteins, there is a continuing need to discover new Ras and Rho family members and their effector proteins that modulate the cytoskeleton, actin polymerization, cell motility and invasion, and the like, and affect proliferation, differentiation, transformation, metastasis and apoptotic pathways. The in vivo activities of both inducers and inhibitors of these pathways illustrate the enormous clinical potential of, and need for, such novel proteins, their agonists and antagonists, for example, in cancer therapy. The present invention addresses this need by providing such polypeptides for these and other uses that should be apparent to those skilled in the art from the teachings herein.
REFERENCES:
patent: 99/51727 (1999-10-01), None
CC Linder, Lab Animal, “The Influence of Genetic Background on Spontaneous and Genetically Engineered Mouse Models of Complex Diseases,” May 2001, vol. 30, No. 5, pp. 34-39.*
Hirsch, DS. et al., EMBL Database, Georgetown University Medical Center, Mar. 11, 1999: AF099664.
Osada, N et al.,J. Human Genetics 45:374-377, 2000.
Joberty, G et al.,Mol. and Cell. Biol. 19:6585-6597, 1999.
Burbelo, P.D. et al.,Proc. Nat'l. Acad. Sci. 96:9083-9088, 1999.
Bahou et al.,J Biol. Chem. 267:13986-13992, 1992.
Burbelo, P.D. et al.,J. Biol. Chem. 270:29071-29074, 1995.
Bahou et al.,J. Biol. Chem. 267:13986-13992, 1992.
Zohn, I.M. et al.,Oncogene 17:1415-1438, 1998.
Adams, MD. et al., Genbank Database, The Institute for Genomic Research, 1993: EST25485.
Wilson RK. et al., Genbank Database, Wash. U. School of Medicine, 1995: EST274424.
Wilson RK. et al., Genbank Database, Wash. U. School of Medicine, 1995: EST626917.
Marra, M. et al., Genbank Database, The WashU-HHMI Mouse EST Project, 1996: EST1166173.
Adams, MD. et al., Genbank Database, The Institute for Genomic Research, 1996: G19982.
Marra, M. et al., Genbank Database, The WashU-HHMI Mouse EST Project, 1996: EST1874398.
Incyte Pharmaceuticals, Inc. clone, 1996: INC1629555.
Incyte Pharmaceuticals, Inc. clone, 1996: INC1686839.
Incyte Pharmaceuticals, Inc. clone, 1996: INC1501852.
Incyte Pharmaceuticals, Inc. clone, 1996: INC1859584.
Incyte Pharmaceuticals, Inc. clone, 1996: INC1916576.
Incyte Pharmaceuticals, Inc. clone, 1996: INC1932856.
Incyte Pharmaceuticals, Inc. clone, 1997: INC2516458.
Incyte Pharmaceuticals, Inc. clone, 1997: INC2737451.
Incyte Pharmaceuticals, Inc. clone, 1997: INC2606509.
Incyte Pharmaceuticals, Inc. clone, 1997: LIN1859584F6.
Incyte Pharmaceuticals, Inc. clone, 1997: INC2744649.
Incyte Pharmaceuticals, Inc. clone, 1997: INC2817289.
Incyte Pharmaceuticals, Inc. clone, 1997: INC2825493.
Incyte Pharmaceuticals, Inc. clone, 1997: INC3151224.
TIGR Tentative Human Consensus, 1997: THC_AA013011.
TIGR Tentative Human Consensus, 1997: : THC_EST04320.
TIGR Tentative Human Consensus, 1997: THC_H14486.
Incyte Pharmaceuticals, Inc. clone, 1997: INC2466008.
Incyte Pharmaceuticals, Inc. clone, 1997: INC3438506.
Incyte Pharmaceuticals, Inc. clone, 1997: INC3507143.
Incyte Pharmaceuticals, Inc. clone, 1997: INC3574066.
Incyte Pharmaceuticals, Inc. clone, 1997: INC3768324.
Incyte Pharmaceuticals, Inc. clone, 1997: INC4079786.
Incyte Pharmaceuticals, Inc. clone, 1997: INC3940912.
Incyte Pharmaceuticals, Inc. clone, 1998: INC4251793.
Incyte Pharmaceuticals, Inc. clone, 1998: INC4182093.
Incyte Pharmaceuticals, Inc. clone, 1998: INC3791270.
Incyte Pharmaceuticals, Inc. clone, 1998: INC4181450.
Incyte Pharmaceuticals, Inc. clone, 1998: INC802504.
Incyte Pharmaceuticals, Inc. Library, 1996: COLNPOT01.
Incyte Pharmaceuticals, Inc. Library, 1996: PROSNOT15.
Incyte Pharmaceuticals, Inc. Library, 1996: SINTBST01.
Incyte Pharmaceuticals, Inc. Library, 1996: PROSNOT18.
Incyte Pharmaceuticals, Inc. Library, 1996: PROSNOT06.
Incyte Pharmaceuticals, Inc. Library, 1996: COLNNOT16.
Incyte Pharmaceuticals, Inc. Library, 1997: LIVRTUT04.
Incyte Pharmaceuticals, Inc. Library, 1997: OVARNOT09.
Incyte Pharmaceuticals, Inc. Library, 1997: LUNGTUT07.
Incyte Pha
Gao Zeren
Holloway James L.
Whitmore Theodore E.
Johnson Jennifer K.
Priebe Scott D.
Whiteman Brian
ZymoGenetics Inc.
LandOfFree
Crib protein ZMSE1 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Crib protein ZMSE1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crib protein ZMSE1 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3095722